A method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels

By detecting changes in the expression of the unspliced ​​precursor and mature ribonucleic acid of the GLT-1 gene and calculating the transcriptional processing index, the problem of delayed early assessment of cellular neurotoxicity in existing technologies has been solved, enabling early and accurate detection of cellular neurotoxicity.

CN123108128APending Publication Date: 2026-11-17南昌大学第一附属医院
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611604936.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to assess cellular neurotoxicity in the early sublethal stages and are susceptible to interference from mature RNA reserves and global nonspecific transcriptional repression, leading to delayed and misjudged results.

Method used

By detecting the relative expression changes of unspliced ​​precursor ribonucleic acid and mature ribonucleic acid of the GLT-1 gene, the transcriptional processing index is calculated. Combined with the quantitative amplification signal of the internal reference gene, a method for comparing the transcriptional processing index with a preset toxicity critical window is constructed to output the cell neurotoxicity level determination result.

Benefits of technology

This enables early assessment of cellular neurotoxicity in the sublethal phase, improves the specificity and accuracy of detection, shortens response time, and reduces the impact of mature RNA reserves and nonspecific transcriptional repression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108128A_ABST
    Figure CN123108128A_ABST
Patent Text Reader

Abstract

This invention relates to the field of cytotoxicity detection technology and discloses a method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels. The method includes: obtaining total ribonucleic acid (RNA) samples from astrocytes in toxic treatment and control groups; constructing a reaction system and simultaneously measuring the quantitative amplification signals of unspliced ​​precursor RNA, mature RNA, and mature RNA of the internal reference gene in the two groups of samples; calculating the relative expression changes of unspliced ​​precursor RNA and mature RNA in the test sample relative to the control sample; calculating the ratio of the two to obtain the transcriptional processing index; and outputting the toxicity level determination result by combining a preset toxicity critical window. This invention, by comparing the expression changes of unspliced ​​precursor RNA and mature RNA of the GLT-1 gene, eliminates global non-specific transcriptional downregulation interference and the masking effect of existing molecules, enabling the assessment of cellular neurotoxicity at the sublethal stage of cell death.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of cytotoxicity detection technology, and more specifically, to a method for detecting cytotoxicity based on GLT-1 transcriptional levels. Background Technology

[0002] Astrocytes in the central nervous system express glutamate transporters, which clear excess glutamate from the synaptic cleft and maintain neuronal homeostasis. When astrocyte function is impaired by exogenous compounds or physical stress, glutamate clearance efficiency decreases, potentially leading to excitatory neurotoxicity. Measuring transcriptional changes in glutamate transporters has become an important approach for assessing cellular neurotoxicity. Current detection techniques mainly use terminal cell damage indicators or real-time quantitative polymerase chain reaction (qPCR) to measure the total expression level of mature RNA in cells. Terminal damage detection typically employs the tetrazolium salt colorimetric method or lactate dehydrogenase release method to measure cell membrane integrity or mitochondrial dehydrogenase activity. Mature RNA quantification uses primers designed for the exon splicing region of the target gene, and calculates the overall transcriptional level through reverse transcription and quantitative amplification.

[0003] Besides the limitations of phenotypic detection based on cell morphology and membrane permeability, the detection of expression levels at the nucleic acid molecular level also has limitations. For example, Chinese invention patent CN102605051B discloses a probe for in situ hybridization of EAAT2 gene cRNA and its design method. This method measures expression changes by constructing a specific probe to hybridize with mature ribonucleic acid in tissue sections. However, such hybridization detection methods can only qualitatively or semi-quantitatively analyze the total amount of statically accumulated mature ribonucleic acid in tissues or cells, and cannot dynamically distinguish between newly transcribed precursor ribonucleic acid in the cell nucleus and mature ribonucleic acid with a high half-life in the cytoplasm. Furthermore, due to the lack of a relative normalization reference for intramolecular dual targets, it cannot eliminate the global non-specific transcriptional downregulation caused by broad-spectrum stress in cells, which can easily lead to the masking and misjudgment of sublethal damage signals, especially in the early stages of toxic exposure. Under sublethal stress conditions, the cell membrane usually remains intact and mitochondrial function has not been lost. Therefore, terminal damage indicators often do not show obvious signal changes and are difficult to reflect early damage in a timely manner. When using the expression level of mature ribonucleic acid for detection, since the half-life of mature ribonucleic acid molecules in the cytoplasm usually exceeds 8 hours, even if the transcription initiation in the cell nucleus has been inhibited, the original mature ribonucleic acid can still maintain a high level for a period of time, thereby masking the changes caused by the reduction of newly synthesized ribonucleic acid and causing the detection results to lag. At the same time, exogenous toxic stimuli can also easily cause non-specific transcriptional inhibition of the whole cell, causing a general decrease in the expression level of multiple genes. Traditional single-target quantitative methods are difficult to distinguish between transcriptional repression of specific glutamate transporter genes and non-specific transcriptional downregulation of the whole cell. Therefore, it is easy to misjudge the general stress response of cells as specific neurotoxic damage.

[0004] Therefore, how to reduce the impact of mature RNA reserves on early detection results and reduce interference from global non-specific transcriptional inhibition and background noise, so as to achieve early assessment and classification of neurotoxicity in sublethal cells, has become a technical problem that needs to be solved. Summary of the Invention

[0005] To address the problems in the background art, this invention provides a method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels, comprising the following steps: Step S1: Obtain total ribonucleic acid samples of astrocytes to be tested after toxic exposure treatment and total ribonucleic acid samples of untreated control astrocytes; Step S2: Using the total ribonucleic acid (RNA) samples of astrocytes to be tested and the total RNA samples of astrocytes in the control group as templates, a reaction system containing specific primer pairs was constructed. The quantitative amplification signals of the unspliced ​​precursor RNA target of the GLT-1 gene, the mature RNA target of the GLT-1 gene, and the mature RNA target of the internal reference gene were measured in parallel in both groups of samples. Among them, the amplification region of the unspliced ​​precursor RNA target spans the intron-exon junction region of the GLT-1 gene, and the amplification region of the mature RNA target spans the exon-exon splicing junction region of the GLT-1 gene. Step S3: Based on the measured quantitative amplification signal, calculate the relative change in the expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the relative change in the expression of the mature ribonucleic acid of the GLT-1 gene in the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group. Step S4: Calculate the ratio of the relative change in expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the relative change in expression of the mature ribonucleic acid of the GLT-1 gene to obtain the transcriptional processing index; Step S5: Compare the transcriptional processing index with the preset toxicity threshold window and output the cellular neurotoxicity level determination result of the astrocytes to be tested.

[0006] Preferably, when constructing the reaction system containing the specific primer pair in step S2, the following sub-steps are included: Step S21, adding deoxyribonuclease to the total ribonucleic acid sample of the astrocytes to be tested and the total ribonucleic acid sample of the control group for digestion; Step S22, adding a specific primer pair targeting the unspliced ​​precursor ribonucleic acid to the reaction system, wherein the 3' end sequence of the upstream primer of the specific primer pair spans the binding site between intron 1 and exon 2 of the GLT-1 gene.

[0007] Preferably, when measuring the quantitative amplification signal in parallel in step S2, a quality control step for the degradation status of ribonucleic acid is included. The quality control step for the degradation status includes the following sub-steps: Step S23, using specific primer pairs targeting the 3' and 5' ends of the internal reference gene, the quantitative amplification signal of the mature ribonucleic acid of the internal reference gene at the 3' end and the quantitative amplification signal at the 5' end are measured respectively; Step S24, the ratio of the quantitative amplification signal at the 3' end to the quantitative amplification signal at the 5' end is calculated to obtain the degradation index; Step S25, the degradation index is compared with a preset integrity threshold. When the degradation index is higher than the preset integrity threshold, the quantitative amplification signal data of the corresponding sample is discarded.

[0008] Preferably, in step S2, the quantitative amplification signal is the cycle threshold measured by real-time quantitative polymerase chain reaction; in step S4, the transcriptional processing index is calculated. The calculation formula is as follows: ,in, This represents the normalized change in the GLT-1 gene unspliced ​​precursor ribonucleic acid (GLT-1) cycling threshold between the tested astrocyte total ribonucleic acid sample and the control astrocyte total ribonucleic acid sample. The normalized change in the GLT-1 gene mature ribonucleic acid cycling threshold of the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group is shown.

[0009] Preferably, in step S5, the preset toxicity threshold window includes a severe toxicity threshold of 0.35 and a moderate stress threshold of 0.75; when the calculated transcriptional processing index is obtained... When the value is less than or equal to 0.35, the output indicates that the tested astrocytes exhibit severe cytotoxicity and GLT-1 gene transcriptional repression; when the transcriptional processing index is less than or equal to 0.35, the output indicates that the tested astrocytes have severe cytotoxicity and GLT-1 gene transcriptional repression. When the value is greater than 0.35 and less than or equal to 0.75, the output indicates that the tested astrocytes exhibit moderate cellular neurotoxicity and metabolic stress; when the transcriptional processing index... When the value is greater than 0.75, the result of determining whether the astrocytes to be tested have no cellular neurotoxicity is output.

[0010] Preferably, in step S2, quantification is performed using a multiplex microfluidic digital polymerase chain reaction. The reaction system contains a first fluorescently labeled probe targeting the unspliced ​​precursor ribonucleic acid (RRNA) of the GLT-1 gene, a second fluorescently labeled probe targeting the mature RRNA of the GLT-1 gene, and a third fluorescently labeled probe targeting the mature RRNA of the internal reference gene. The fluorescence signal of the microfluidic reaction droplets is read, and the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the absolute copy number of the mature RRNA of the GLT-1 gene are calculated based on a Poisson distribution model. In step S4, the direct ratio of the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the absolute copy number of the mature RRNA of the GLT-1 gene is used as the absolute transcriptional processing index.

[0011] Preferably, after step S5, the following sub-steps are also included: Step S51, extracting the genomic deoxyribonucleic acid of the astrocytes to be tested after toxic exposure treatment, and after bisulfite treatment, determining the methylation percentage of the CpG island in the promoter region of the GLT-1 gene using methylation-specific polymerase chain reaction; Step S52, multiplying the transcriptional processing index by the methylation percentage to obtain a comprehensive toxicity index, and outputting the differentiation results characterizing acute metabolic repression neurotoxicity and epigenetic silent chronic toxicity based on the value range of the comprehensive toxicity index.

[0012] Preferably, in step S1, the toxicity exposure treatment involves adding the test compound to a culture system containing astrocytes and incubating it.

[0013] Preferably, the target site of the internal reference gene mature ribonucleic acid is the mature ribonucleic acid of the ACTB gene in rodents; the amplification region of the target site of the mature ribonucleic acid of the GLT-1 gene spans the splicing junction region of exon 4 and exon 5 of the GLT-1 gene.

[0014] Preferably, in step S1, the toxicity exposure treatment involves placing the culture system containing astrocytes in a hypoxic and hypoglycemic environment for induction, followed by normoxic reglycemic reperfusion after induction.

[0015] The above embodiments of the present invention have at least the following beneficial effects: 1. In the detection of cellular neurotoxicity at the GLT-1 transcriptional level, comparing the expression changes of unspliced ​​precursor ribonucleic acid (RRNA) and mature ribonucleic acid (MRNA) of the GLT-1 gene can more timely reflect the suppression of new GLT-1 gene transcription. Since the RRNA changes rapidly, while the mature ribonucleic acid already present in the cytoplasm is relatively stable, combining the two for judgment can reduce the signal lag caused by the amount of mature ribonucleic acid. Therefore, transcriptional abnormalities can be detected in the sublethal stage before obvious structural damage to the cell occurs, shortening the response time of neurotoxicity detection and improving the ability to identify early damage.

[0016] 2. This invention utilizes ribonucleic acid from different splicing states of the same GLT-1 gene for cross-reference, so that the detection results no longer solely depend on the increase or decrease of the expression level of a single target. By comparing the relative changes between the treatment group and the control group, the influence of global non-specific transcriptional downregulation, differences in the number of initiating cells, and nucleic acid extraction loss on the detection results can be reduced. This allows for a more accurate distinction between transcriptional repression of the GLT-1 gene itself and the general stress response of cells, reducing misjudgments caused by non-specific changes and improving the specificity and accuracy of cellular neurotoxicity detection.

[0017] 3. This invention reduces non-specific amplification caused by residual genomic deoxyribonucleic acid by using deoxyribonuclease digestion and specific primer design across the binding site. At the same time, by combining quantitative amplification signals from different positions of the internal reference gene to check the degradation status of ribonucleic acid, samples with severe degradation can be identified and excluded before calculation. This reduces the impact of genomic residues and sample degradation on quantitative results, making the obtained amplification signals more reflective of the actual changes in intact target ribonucleic acid, and improving the stability and repeatability of the detection process. Attached Figure Description

[0018] The above and other objects, features, and advantages of exemplary embodiments of the present invention will become readily apparent from the following detailed description taken in conjunction with the accompanying drawings, in which several embodiments of the invention are illustrated by way of example and not limitation, wherein: Figure 1This is a flowchart illustrating the calculation of the relative expression levels of the two targets and the transcriptional processing index in this invention. Figure 2 This is an analytical structural diagram of the microfluidic reaction system and Poisson distribution of the present invention. Detailed Implementation

[0019] The principles and spirit of the present invention will now be described with reference to several exemplary embodiments in conjunction with the accompanying drawings. It should be understood that these embodiments are provided merely to enable those skilled in the art to better understand and implement the present invention, and are not intended to limit the scope of the present invention in any way. On the contrary, these embodiments are provided to make the present invention more thorough and complete, and to fully convey the scope of the present invention to those skilled in the art.

[0020] A method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels includes the following steps: Step S1: Obtain total ribonucleic acid samples of astrocytes to be tested after toxic exposure treatment and total ribonucleic acid samples of untreated control astrocytes; Step S2: Using the total ribonucleic acid (RNA) samples of astrocytes to be tested and the total RNA samples of astrocytes in the control group as templates, a reaction system containing specific primer pairs was constructed. The quantitative amplification signals of the unspliced ​​precursor RNA target of the GLT-1 gene, the mature RNA target of the GLT-1 gene, and the mature RNA target of the internal reference gene were measured in parallel in both groups of samples. Among them, the amplification region of the unspliced ​​precursor RNA target spans the intron-exon junction region of the GLT-1 gene, and the amplification region of the mature RNA target spans the exon-exon splicing junction region of the GLT-1 gene. Step S3: Based on the measured quantitative amplification signal, calculate the relative change in the expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the relative change in the expression of the mature ribonucleic acid of the GLT-1 gene in the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group. Step S4: Calculate the ratio of the relative change in expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the relative change in expression of the mature ribonucleic acid of the GLT-1 gene to obtain the transcriptional processing index; Step S5: Compare the transcriptional processing index with the preset toxicity threshold window and output the cellular neurotoxicity level determination result of the astrocytes to be tested.

[0021] Preferably, when constructing the reaction system containing the specific primer pair in step S2, the following sub-steps are included: Step S21, adding deoxyribonuclease to the total ribonucleic acid sample of the astrocytes to be tested and the total ribonucleic acid sample of the control group for digestion; Step S22, adding a specific primer pair targeting the unspliced ​​precursor ribonucleic acid to the reaction system, wherein the 3' end sequence of the upstream primer of the specific primer pair spans the binding site between intron 1 and exon 2 of the GLT-1 gene.

[0022] Preferably, when measuring the quantitative amplification signal in parallel in step S2, a quality control step for the degradation status of ribonucleic acid is included. The quality control step for the degradation status includes the following sub-steps: Step S23, using specific primer pairs targeting the 3' and 5' ends of the internal reference gene, the quantitative amplification signal of the mature ribonucleic acid of the internal reference gene at the 3' end and the quantitative amplification signal at the 5' end are measured respectively; Step S24, the ratio of the quantitative amplification signal at the 3' end to the quantitative amplification signal at the 5' end is calculated to obtain the degradation index; Step S25, the degradation index is compared with a preset integrity threshold. When the degradation index is higher than the preset integrity threshold, the quantitative amplification signal data of the corresponding sample is discarded.

[0023] Preferably, in step S2, the quantitative amplification signal is the cycle threshold measured by real-time quantitative polymerase chain reaction; in step S4, the transcriptional processing index is calculated. The calculation formula is as follows: ,in, This represents the normalized change in the GLT-1 gene unspliced ​​precursor ribonucleic acid (GLT-1) cycling threshold between the tested astrocyte total ribonucleic acid sample and the control astrocyte total ribonucleic acid sample. The normalized change in the GLT-1 gene mature ribonucleic acid cycling threshold of the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group is shown.

[0024] Preferably, in step S5, the preset toxicity threshold window includes a severe toxicity threshold of 0.35 and a moderate stress threshold of 0.75; when the calculated transcriptional processing index is obtained... When the value is less than or equal to 0.35, the output indicates that the tested astrocytes exhibit severe cytotoxicity and GLT-1 gene transcriptional repression; when the transcriptional processing index is less than or equal to 0.35, the output indicates that the tested astrocytes have severe cytotoxicity and GLT-1 gene transcriptional repression. When the value is greater than 0.35 and less than or equal to 0.75, the output indicates that the tested astrocytes exhibit moderate cellular neurotoxicity and metabolic stress; when the transcriptional processing index... When the value is greater than 0.75, the result of determining whether the astrocytes to be tested have no cellular neurotoxicity is output.

[0025] Preferably, in step S2, quantification is performed using a multiplex microfluidic digital polymerase chain reaction. The reaction system contains a first fluorescently labeled probe targeting the unspliced ​​precursor ribonucleic acid (RRNA) of the GLT-1 gene, a second fluorescently labeled probe targeting the mature RRNA of the GLT-1 gene, and a third fluorescently labeled probe targeting the mature RRNA of the internal reference gene. The fluorescence signal of the microfluidic reaction droplets is read, and the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the absolute copy number of the mature RRNA of the GLT-1 gene are calculated based on a Poisson distribution model. In step S4, the direct ratio of the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the absolute copy number of the mature RRNA of the GLT-1 gene is used as the absolute transcriptional processing index.

[0026] Preferably, after step S5, the following sub-steps are also included: Step S51, extracting the genomic deoxyribonucleic acid of the astrocytes to be tested after toxic exposure treatment, and after bisulfite treatment, determining the methylation percentage of the CpG island in the promoter region of the GLT-1 gene using methylation-specific polymerase chain reaction; Step S52, multiplying the transcriptional processing index by the methylation percentage to obtain a comprehensive toxicity index, and outputting the differentiation results characterizing acute metabolic repression neurotoxicity and epigenetic silent chronic toxicity based on the value range of the comprehensive toxicity index.

[0027] Preferably, in step S1, the toxicity exposure treatment involves adding the test compound to a culture system containing astrocytes and incubating it.

[0028] Preferably, the target site of the internal reference gene mature ribonucleic acid is the mature ribonucleic acid of the ACTB gene in rodents; the amplification region of the target site of the mature ribonucleic acid of the GLT-1 gene spans the splicing junction region of exon 4 and exon 5 of the GLT-1 gene.

[0029] Preferably, in step S1, the toxicity exposure treatment involves placing the culture system containing astrocytes in a hypoxic and hypoglycemic environment for induction, followed by normoxic reglycemic reperfusion after induction.

[0030] Example 1: In the assessment of hypoxia- and hypoglycemia-induced early damage to primary rat astrocytes, the seeding density was [not specified]. Astrocytes per cell / well were placed in a sugar-free culture medium containing... and After 2 hours of exposure to hypoxia and 4 hours of reperfusion following normoxic conditions, the cell membrane structure remained intact and cell viability was 92.4% as measured by the tetrazolium salt colorimetric method. However, the initiation of transcription of the glutamate transporter-1 gene (GLT-1) in the cell nucleus was inhibited. The total expression level was downregulated due to the half-life of mature ribonucleic acid in the cytoplasm exceeding 8 hours. Furthermore, the global non-specific transcriptional inhibition induced by exogenous stress caused background noise interference in single-target detection.

[0031] Total ribonucleic acid (RNA) was extracted from cells in the treatment group and the normoxic culture control group and dissolved in nuclease-free water. The RNA concentration in the control group was measured to be 152.4 ng / μL, and the absorbance ratio was [not specified]. The value was 2.02, the RNA concentration in the treatment group was 138.6 ng / μL, and the absorbance ratio was 2.02. The concentration was 1.98. Deoxyribonuclease I was added to the reverse transcription forward system to eliminate interference from residual genomic deoxyribonucleic acid. The specific primer sequences used for each target in this embodiment were designed based on the rat GLT-1 gene sequence (GenBank accession number NM_017215.2), the rat GLT-1 genome reference sequence (NC_051338.1), and the rat ACTB gene sequence (GenBank accession number NM_031144.3). All primers were chemically synthesized by a commercial gene synthesis institution using the solid-phase phosphoramidite method and purified by denaturing polyacrylamide gel electrophoresis (PAGE) before use. Specifically, a specific primer pair with the 3' end sequence of the upstream primer spanning the junction of intron 1 and exon 2 of the GLT-1 gene was selected to amplify unspliced ​​precursor ribonucleic acid target A. The nucleotide sequence of the upstream primer preGLT1-F in the specific primer pair targeting unspliced ​​precursor ribonucleic acid target A is shown in the sequence listing SEQ ID NO: As shown in SEQ ID NO: 1 (5'-GTCCTGTGTGCTTCAGCTTG-3'), its 3' end sequence is located and spans the junction site between intron 1 and exon 2 of the GLT-1 gene. The nucleotide sequence of the downstream primer preGLT1-R is shown in SEQ ID NO: 2 of the sequence listing (5'-GATGCCTCCTCTACCTCCTG-3'), and the amplified fragment length is 118 bp. A specific primer pair spanning the splicing junction region between exon 4 and exon 5 of the GLT-1 gene was used to amplify mature ribonucleic acid target B. In the specific primer pair for mature ribonucleic acid target B, the nucleotide sequence of the upstream primer matGLT1-F is shown in SEQ ID NO: 3 of the sequence listing (5'-GGCACCATCGTCTTCTCCAT-3'), and the nucleotide sequence of the downstream primer matGLT1-R is shown in SEQ ID NO: 3 of the sequence listing. As shown in SEQ ID NO: 4 (5'-CGGTCATTCCTGTCCACACC-3'), the amplified fragment spans the splicing junction region of exon 4 and exon 5, and the amplified product length is 105bp. Simultaneously, the mature ribonucleic acid of the rodent ACTB gene is used as the internal reference gene target C. In the specific primer pair for the internal reference gene target C, the nucleotide sequence of the upstream primer ACTB-F is shown in SEQ ID NO: 5 in the sequence listing (5'-AGATCAAGATCATTGCTCCTCCT-3'), and the nucleotide sequence of the downstream primer ACTB-R is shown in SEQ ID NO: 6 in the sequence listing (5'-ACGCAGCTCAGTAACAGTCC-3'), and the amplified fragment length is 115bp.Specific primer pairs targeting the 3' and 5' ends of the ACTB gene were introduced into the amplification system. For the 3' end of the ACTB gene, the upstream primer ACTB-3'-F has the nucleotide sequence shown in SEQ ID NO: 7 (5'-GCTATGTTGCCCTAGACTTCGA-3'), and the downstream primer ACTB-3'-R has the nucleotide sequence shown in SEQ ID NO: 8 (5'-GATGCCGTGCTCGATGGGGTA-3'). The amplified fragment is located proximal to the untranslated region at the 3' end of the ACTB gene transcript and is 102 bp in length. For the 5' end of the ACTB gene, the upstream primer ACTB-5'-F has the nucleotide sequence shown in SEQ ID NO: 9 (5'-ATCGTGGGCCGCCCTAGGCA-3'), and the downstream primer ACTB-5'-R has the nucleotide sequence shown in SEQ ID NO: 9. As shown in Figure 10 (5'-TGGCCTTAGGGTTCAGGGGGG-3'), the amplified fragment is located in the 5' start coding region of the ACTB gene and has a length of 108 bp; the treatment group was determined. and The degradation index is obtained by calculating the ratio of the 3' end quantitative amplification signal to the 5' end quantitative amplification signal. ,in, The degradation index, The 3' end cycling threshold of the internal reference gene. The 5' end cycling threshold of the internal reference gene; calculated as follows The sample was deemed to have passed quality control.

[0032] The cycle threshold of the control group was obtained by parallel measurement using real-time quantitative polymerase chain reaction. , and Processing group cycle threshold , and The normalized change in the cycling threshold of the unspliced ​​precursor ribonucleic acid was calculated as follows: Normalized change in the mature ribonucleic acid cycling threshold: This yielded the relative change in the expression of the unspliced ​​precursor RNA of the GLT-1 gene. The relative change in the expression of mature GLT-1 gene RNA The transcription processing index is obtained by calculating the ratio of the two: ,in, This is a transcriptional processing index. This represents the normalized change in the GLT-1 gene unspliced ​​precursor ribonucleic acid (GLT-1) cycling threshold between the tested astrocyte total ribonucleic acid sample and the control astrocyte total ribonucleic acid sample. This represents the normalized change in the GLT-1 gene mature ribonucleic acid cycling threshold of the total ribonucleic acid sample from the test astrocytes relative to the total ribonucleic acid sample from the control astrocytes. and These represent the precursor RNA cycling thresholds for the treatment and control groups, respectively. and These represent the mature RNA cycling thresholds for the treatment and control groups, respectively. and The internal reference gene cycling thresholds for the treatment and control groups were used, respectively. The real-time transcription level was reflected by the unspliced ​​precursor ribonucleic acid with a short half-life, while homologous mature ribonucleic acid was used as a control. The ratio of the two to form an intramolecular reference can reduce the impact of global non-specific transcription downregulation and extraction loss.

[0033] Compared with the preset toxicity critical window, the measured If the result falls within the threshold range of 0.35 (less than or equal to the severe toxicity threshold), the results of 4 hours of hypoxia-glucose deprivation treatment inducing severe cellular neurotoxicity and GLT-1 gene transcriptional repression in astrocytes are output. Compared with the limitation of traditional colorimetric methods that do not have a signal response in the pre-death stage of cells, this method obtains early transcriptional repression signals in the sublethal stress stage, realizing dynamic assessment of cell damage based on nucleic acid transcriptional processing.

[0034] Example 2: In this example, human astrocytes (HA) seeded in 24-well plates were used for screening the neurotoxicity of the candidate compound Comp-A and for dose-dependent evaluation. Cells were divided into three groups: the present invention sample group (exposed for 6 hours), a conventional colorimetric control group, and a single-target nucleic acid control group. The Comp-A concentrations in the present invention sample group were set to 0 μM, 1 μM, 10 μM, 50 μM, and 100 μM, respectively. The concentration of dimethyl sulfoxide (DMSO) was uniformly maintained at 0.1%. To simulate background noise and non-specific transcriptional interference in an industrial testing environment, Gaussian white noise with a signal-to-noise ratio of 20 dB and a 50 Hz electrical signal perturbation were superimposed on the culture system. After exposure, cells were lysed, total ribonucleic acid was extracted and dissolved in nuclease-free water. The absorbance ratios of the samples from each group were compared. The values ​​ranged from 1.91 to 2.05. Before reverse transcription, deoxyribonuclease I was added to digest the residual genomic DNA. Simultaneously, quantitative amplification signals were measured using specific primer pairs targeting the 3' and 5' ends of ACTB. The degradation index of each group was also analyzed. All values ​​were between 1.08 and 1.35, meeting the requirements for determining the preset integrity threshold, and the samples passed quality control.

[0035] Under the above detection conditions, external physical noise and electrical signal disturbances act on the signal acquisition circuit and temperature control module of the fluorescence detection sensor through electromagnetic induction and micro-thermal effects, causing non-specific baseline drift and high-frequency fluctuations in fluorescence signal reading. The unspliced ​​precursor ribonucleic acid target and the mature ribonucleic acid target are located in the same reaction microregion and are acquired in parallel under the same electromagnetic and temperature environment. The physical disturbance has a proportional and same-direction effect on the fluorescence intensity acquisition efficiency of both. After calculating the ratio of the real-time expression levels of the two, the environmental noise and temperature drift interference that change in the same direction are canceled out in the ratio, which is used to reduce the influence of physical environmental noise on the determination of transcriptional repression signal.

[0036] The cycling thresholds of GLT-1 gene unspliced ​​precursor ribonucleic acid (GLT-1), mature GLT-1, and mature ACTB reference gene (ACTB reference gene) were measured in parallel using real-time quantitative polymerase chain reaction (qPCR). Based on the normalized relationship between the cycling thresholds of the treatment and control groups and the ACTB reference gene, the normalized change in the cycling threshold of GLT-1 gene unspliced ​​precursor ribonucleic acid was obtained. Normalized change in the GLT-1 gene mature ribonucleic acid cycling threshold Then, the transcriptional processing index is calculated based on the relative changes in expression between the two. Simultaneously, high performance liquid chromatography was used to determine the residual glutamate in the culture medium and to calculate the glutamate clearance rate of astrocytes. Cell viability was determined using the tetrazolium salt colorimetric method.

[0037] When the Comp-A dosage is 0 μM It is 0.00. The value is 0.00, from which we obtain The value was 1.0000; the corresponding glutamate clearance rate was 14.8 nmol / min / mg protein, and the cell viability was 100.0%. After increasing the drug concentration to 1 μM, It is 0.28. The value was 0.05, obtained by converting the relative change in expression and calculating the ratio. The value was 0.8527; at this point, the glutamate clearance rate was 14.2 nmol / min / mg protein, and the cell viability was 98.6%. If the value is above the moderate stress threshold of 0.75, a result indicating no cellular neurotoxicity is output.

[0038] When the Comp-A concentration was increased to 10 μM Increased to 0.85, The value is 0.20. The magnitude of the nascent transcriptional change corresponding to precursor RNA is greater than that of mature RNA, and the same calculation relationship is applied. The value was 0.6372, falling within the preset toxicity threshold window of greater than 0.35 and less than or equal to 0.75. The result of the judgment of moderate cellular neurotoxicity and metabolic stress was output. Compared with the 0 μM group, the glutamate clearance rate decreased from 14.8 nmol / min / mg protein to 9.2 nmol / min / mg protein, a decrease of 37.8%, while the cell viability was still 96.1%. At this cell viability level, conventional terminal injury indicators did not show the same change as the decrease in glutamate clearance function, while the transcriptional processing index had entered the moderate stress judgment range.

[0039] When the Comp-A concentration was further increased to 50 μM, It is 2.40. It is 0.60, obtained by the same process. The value was 0.2872, falling within the range of 0.35 or less for severe cytotoxicity and GLT-1 gene transcriptional repression. The results for severe cytotoxicity and GLT-1 gene transcriptional repression were output. At this point, the glutamate clearance rate decreased to 3.1 nmol / min / mg protein, a 79.1% decrease compared to the 0 μM group, while cell viability remained at 91.5%. To further investigate the differences in detection time and judgment results between the method of this invention and the single-target mature ribonucleic acid method and the tetrazolium salt colorimetric method under the same cell and exposure conditions, parallel time-course kinetic measurements were performed on three groups of cells at 50 μM concentration for 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h of exposure. The single-target nucleic acid control group only amplified the mature ribonucleic acid target of the GLT-1 gene, and the relative expression level was calculated using the internal reference gene ACTB normalization. According to conventional transcriptional repression standards, a relative downregulation of more than 50% is considered... A value less than or equal to 0.50 was used as the positive criterion; the standard colorimetric control group used CCK-8 reagent to measure the absorbance at 450 nm. The cell viability was calculated and converted, and a positive result was determined according to the general in vitro toxicity standard, which used a cell viability of less than 80%.

[0040] The results of parallel time-course kinetic assays showed that, after 1 hour of exposure, the initiation of new transcription of the GLT-1 gene was rapidly repressed. The results obtained from the sample group of this invention... 0.82 The value is 0.08, and the calculated value is... The expression level dropped to 0.5987, falling into the range greater than 0.35 and less than or equal to 0.75, successfully detecting moderate cellular neurotoxicity and metabolic stress. This was the earliest time point at which the dual-target method of this invention showed a positive result. At this time, the relative expression level of the single-target nucleic acid control group was 0.9461, which was considered negative, and the cell viability of the conventional colorimetric control group was 99.1%, which was considered non-toxic. After 4 hours of exposure treatment, the sample group of this invention measured... 2.15 0.38 The value was 0.2932, falling into the less than or equal to 0.35 range for the first time and triggering a severe cytotoxicity assessment. At this point, the relative expression level of the single-target nucleic acid control group was 0.7684, still negative, and the cell viability of the conventional colorimetric control group was 95.2%, still negative. After 6 hours of exposure, the sample group of this invention... The relative expression level in the single-target nucleic acid control group was 0.2872, maintaining a high toxicity level. The relative expression level in the single-target nucleic acid control group was 0.6598, still negative. The cell viability in the conventional colorimetric control group was 91.5%, also negative. After 8 hours of exposure, due to the natural decay of existing mature ribonucleic acid molecules, the single-target nucleic acid control group showed a lower relative expression level. Reaching 1.12 corresponds to a relative expression level decreasing to 0.4599 and breaking through the threshold of less than or equal to 0.50 for the first time. This is the earliest time point for a positive result using the single-target method, but it is 7 hours later than the initial positive detection time of the method of this invention. At this time, the cell viability of the conventional colorimetric control group is 87.3%, which is still negative. After 12 hours of exposure, cell membrane permeability and mitochondrial dehydrogenase function are damaged. The cell viability of the conventional colorimetric control group is reduced to 76.8% and breaks through the toxicity threshold of less than 80% for the first time. This is the earliest time point for a positive result using the colorimetric method, but it is 11 hours later than the initial positive detection time of the method of this invention. After 24 hours of exposure, the relative expression level of the single-target nucleic acid control group is reduced to 0.1818, and the cell viability of the conventional colorimetric control group is reduced to 54.2%. Both control groups show late severe damage signals.

[0041] The parallel time-course comparison experiment of the three methods under the same cell and the same exposure conditions showed that the earliest time point for positive judgment of the dual-target detection method based on GLT-1 transcriptional processing index of the present invention is 1 hour after exposure treatment. Compared with the single-target mature ribonucleic acid method, the detection time is shortened by 7 hours, and compared with the conventional terminal colorimetric method, the detection time is shortened by 11 hours. By directly eliminating the masking effect of existing mature molecules and non-specific background interference, it achieves sensitive and rapid detection of cellular neurotoxicity in the sublethal early window stage when the cell morphology is intact and the metabolism is compensated.

[0042] When the Comp-A concentration was increased to 100 μM It further increased to 3.82. Increased to 1.85, the calculated value is... The concentration was 0.2552; the glutamate clearance rate decreased to 1.1 nmol / min / mg protein, and cell viability decreased to 78.3%. When the concentration was increased from 50 μM to 100 μM, The TPI decreased from 0.2872 to 0.2552 and approached a plateau, corresponding to the monotonic physiological limit of complete loss of glutamate clearance. In the three-tiered classification of the preset toxicity threshold window, the assignment of the two critical endpoints, 0.35 and 0.75, was determined based on the principle of conservative early warning of sublethal physiological responses. The endpoint value of 0.75 represents the critical upper limit of astrocyte regeneration and transcriptional compensation. Experiments showed that when the TPI decreased to 0.7500, the glutamate clearance rate had already undergone a measurable downregulation of approximately 15% compared to the baseline state of 14.8 nmol / min / mg protein, indicating that the transcriptional microenvironment had been disrupted by early exogenous stress. This classification of values ​​greater than 0.35 and less than or equal to 0.75 into the moderate cytotoxicity and metabolic stress range prevents early sublethal stress signals from being misinterpreted as normal and non-toxic. The endpoint value of 0.35 represents the inflection point of glutamate homeostasis compensation exhaustion. When TPI equals 0.3500, the astrocyte glutamate clearance rate decreases by more than 70%, and the initiation of new transcription is irreversibly inhibited. Therefore, it is included in the severe cytotoxicity and GLT-1 gene transcriptional repression range of 0.35 and less, ensuring a strict definition of severe transcriptional repression. The values ​​obtained from the 0 μM, 1 μM, 10 μM, 50 μM, and 100 μM groups... The data successively crosses three judgment intervals: greater than 0.75, greater than 0.35 and less than or equal to 0.75, and less than or equal to 0.35, and corresponds to changes in glutamate clearance rate and cell viability. It provides experimental data and physiological mechanism correspondence for the preset toxicity critical windows of less than or equal to 0.35, greater than 0.35 and less than or equal to 0.75, and greater than 0.75.

[0043] Through the above concentration gradient experiments, the normalized change in the cycling threshold of unspliced ​​precursor ribonucleic acid (GLT-1) changed significantly before that of mature ribonucleic acid as the Comp-A concentration increased, and the corresponding transcriptional processing index gradually decreased from 1.0000 to 0.2552. When cell viability remained at a high level, the transcriptional processing index had already entered the range for determining moderate or severe cellular neurotoxicity, and changed synchronously with the decrease in glutamate clearance rate. Therefore, when the cell physical structure remained intact and the changes in conventional colorimetric detection were not yet obvious, cellular neurotoxicity could be graded based on the relative expression changes and ratio of unspliced ​​precursor ribonucleic acid to mature ribonucleic acid of the GLT-1 gene.

[0044] Example 3: After rat primary astrocytes were subjected to severe hypoxia and glucose deficiency and stimulated by high concentrations of exogenous neurotoxic compounds, the residual genomic deoxyribonucleic acid in the cell lysis products could generate pseudo-amplification signals during the amplification of unspliced ​​precursor ribonucleic acid targets, lowering the unspliced ​​precursor ribonucleic acid cycle threshold and causing an elevated transcription processing index. At the same time, ribonucleic acid degradation caused by extreme stress would lead to differences in amplification efficiency in different amplification regions, thereby affecting the correspondence between the quantitative results of unspliced ​​precursor ribonucleic acid and mature ribonucleic acid. In this example, the above two types of interference were controlled by comparing the quantitative amplification signals at the 3' and 5' ends of the ACTB gene through deoxyribonuclease digestion and ACTB gene 3' and 5' end quantitative amplification signals, respectively.

[0045] 1 U of deoxyribonuclease I and its reaction buffer were added to 1 μg of total cellular RNA extract, and nuclease-free water was added to bring the total volume to 10 μL. The mixture was heated in a 37°C water bath for 15 min to digest genomic DNA. Subsequently, 1 μL of 50 mM EDTA solution was added, and the enzyme digestion reaction was terminated by inactivation at 65°C for 10 min. PCR amplification was performed using a specific primer pair that spanned the binding site between intron 1 and exon 2 of the GLT-1 gene. The cycle threshold of the undigested reverse transcriptase control well was 28.50, while the cycle threshold of the digested reverse transcriptase control well was greater than 38.00 or there was no amplification signal. Based on the difference in cycle threshold, the design of deoxyribonuclease I digestion combined with the upstream primer crossing the binding site at the 3' end reduced the pseudo-amplification efficiency of residual genomic DNA by more than 1000 times.

[0046] For four groups of ribonucleic acid samples that underwent varying degrees of degradation after treatment with high concentrations of toxins, after constructing a 20 μL reaction system using reverse transcription, the cycling thresholds at the 3' and 5' ends of the ACTB gene were detected in parallel using real-time quantitative polymerase chain reaction. Sample 1 was measured to... , Sample 2 was measured , Sample 3 was measured , Sample 4 was measured , After converting the 3' and 5' end cycle thresholds into corresponding quantitative amplification signals, the ratio of the 3' end quantitative amplification signal to the 5' end quantitative amplification signal is calculated to obtain the degradation index. The calculation relationship is as follows: Based on the above test results, the value of sample 1 was calculated to be... Sample 2 Sample 3 Sample 4 In Sample 1, the ratio of unspliced ​​precursor GLT-1 RNA to mature GLT-1 RNA remained stable. In Samples 2, 3, and 4, RNA breakage caused asymmetric decay in primer binding and amplification efficiency in different amplification regions, resulting in a significant non-linear deviation in the transcriptional processing index. Based on the correlation between the degradation index of the four samples and the stability of the ratio of unspliced ​​precursor GLT-1 RNA to mature GLT-1 RNA, [the following was determined]. Set as a preset integrity threshold; when At that time, the quantitative amplification signal data of the corresponding sample should be discarded.

[0047] By using the above-mentioned deoxyribonuclease digestion and ribonucleic acid degradation status quality control, corresponding interfering samples can be identified and removed in the presence of genomic deoxyribonucleic acid residues and ribonucleic acid degradation. This ensures that the subsequent cycle threshold data comes from ribonucleic acid samples that meet the integrity requirements, and is used for the quantification of unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the calculation of the transcriptional processing index of mature ribonucleic acid of the GLT-1 gene.

[0048] Example 4: This example combines Figures 1 to 2 This paper describes a method for detecting cellular neurotoxicity based on GLT-1 transcription levels, such as... Figure 1 As shown, in step S1, total ribonucleic acid (RNA) samples of astrocytes to be tested after toxic exposure treatment and total RNA samples of untreated control astrocytes were obtained. Then, in step S2, a reaction system containing specific primer pairs was constructed using the total RNA samples of the test and control astrocytes as templates. Quantitative amplification signals of the unspliced ​​precursor RNA target, mature RNA target, and internal reference gene target of the GLT-1 gene were measured in both groups of samples. Subsequently, in step S3, based on the measured quantitative amplification signals, the RNA of the test astrocytes was calculated. The relative changes in the expression of GLT-1 gene unspliced ​​precursor ribonucleic acid and mature ribonucleic acid of total ribonucleic acid samples of glial cells compared with control samples were measured. Then, in step S4, the ratio of the relative change in the expression of GLT-1 gene unspliced ​​precursor ribonucleic acid to the relative change in the expression of GLT-1 gene mature ribonucleic acid was calculated to obtain the transcriptional processing index. Finally, in step S5, the transcriptional processing index was compared with a preset toxicity threshold window to output the cellular neurotoxicity level determination result of the astrocytes to be tested.

[0049] like Figure 2As shown, in the astrocyte culture system, an anaerobic and glucose-deficient environment is applied to astrocytes. After treatment, total ribonucleic acid (RNA) samples are extracted and output. Deoxyribonuclease is used to digest the RNA samples. The digested RNA samples are then introduced into a microfluidic chip within the reaction system. The reaction system is also equipped with specific primer pairs, a temperature control module, and a fluorescence detection sensor. The fluorescence detection sensor monitors the amplification process in real time within the reaction system and outputs a quantitative amplification signal to determine the toxicity level. In the toxicity level determination, a Poisson distribution model is used to calculate the input quantitative amplification signal to obtain the cellular neurotoxicity determination result.

[0050] Example 5: This example describes the offline calibration of basal transcriptional levels in different batches of primary rat astrocytes. Control cells (without the analyte) were added to 96-well plates and incubated at 37°C for 2 hours. Total ribonucleic acid (RNA) was extracted, and the basal cycle threshold was determined using quantitative real-time polymerase chain reaction (qPCR). When the precursor RNA of the control group... Mature ribonucleic acid (RNA) in the range of 23.80 to 24.50 Within the range of 18.20 to 18.80, and the internal reference gene When the value is between 16.00 and 16.50, the average value of this group of measurements should be used as the reference parameter for this batch of cells; if the initial cycle threshold deviates from the above range, the cell seeding density should be adjusted to [the specified value]. The baseline cycle threshold was re-determined after cells / well to provide a normalized input for calculating the relative expression change after subsequent toxic exposure.

[0051] In the discrete absolute quantification process of multiplex microfluidic digital polymerase chain reaction, the reverse-transcribed complementary deoxyribonucleic acid (cDNA) system was dispersed into 20,000 independent reaction droplets on a microfluidic chip. A first fluorescently labeled probe targeting the unspliced ​​precursor ribonucleic acid of the GLT-1 gene, a second fluorescently labeled probe targeting the mature ribonucleic acid of the GLT-1 gene, and a third fluorescently labeled probe targeting the mature ribonucleic acid of the internal reference gene were added to the reaction system. All fluorescent probes were prepared by a commercial synthetic institution using solid-phase chemical synthesis and purified by high-performance liquid chromatography (HPLC) to a purity greater than 98%. Specifically, the first fluorescently labeled probe, Probe-pre, was designed to target the exon 2 amplification region of the unspliced ​​precursor ribonucleic acid target, and its nucleotide sequence is shown in the sequence listing SEQ ID NO: As shown in SEQ ID NO: 11 (5'-CGGTTCCTGGACACCTCGTG-3'), the 5' end of the probe is covalently modified with a FAM fluorescent reporter group, and the 3' end is covalently modified with a BHQ1 fluorescent quencher group; the second fluorescently labeled probe, Probe-mat, is designed for the splicing region between exon 4 and exon 5 of the mature ribonucleic acid target, and its nucleotide sequence is shown in SEQ ID NO: 12 (5'-ATCTTCCTGCCTGGCATCGTGG-3'), the 5' end of the probe is covalently modified with a VIC fluorescent reporter group, and the 3' end is covalently modified with a BHQ1 fluorescent quencher group; the third fluorescently labeled probe, Probe-ref, is designed for the mature target region of the ACTB gene coding region, and its nucleotide sequence is shown in SEQ ID NO: 12. As shown in Figure 13 (5'-TGCGTGACATCAAAGAGAAGCTGTGC-3'), the 5' end of the probe is covalently modified with a CY5 fluorescent reporter group, and the 3' end is covalently modified with a BHQ2 fluorescent quencher group. The number of positive droplets at the unspliced ​​precursor ribonucleic acid target in the FAM fluorescent channel and the number of positive droplets at the mature ribonucleic acid target in the VIC fluorescent channel are read. Simultaneously, the fluorescence signal corresponding to the third fluorescently labeled probe, i.e., the number of positive droplets at the mature ribonucleic acid target of the internal reference gene in the CY5 fluorescent channel, is read. The absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene is calculated based on the Poisson distribution model. The absolute copy number of mature ribonucleic acid of the GLT-1 gene and will and The direct ratio of the two is used as the absolute transcriptional processing index. .

[0052] When the fluorescence background signal drift causes the total number of effective droplets to fall below 12,000, baseline threshold correction is automatically triggered and the channel fluorescence threshold is adjusted to measure the non-toxic exposure control group. Severe toxicity exposure group The absolute transcriptional processing index of the severe toxicity exposure group was below the critical value of 0.1200, and the output was the assessment result of severe transcriptional termination and cellular neurotoxicity.

[0053] During the baseline threshold correction process, the fluctuation of the fluorescence background baseline of all reacting droplets is monitored in real time. The mean fluorescence intensity of template-free negative droplets plus three times the standard deviation is used as the initial judgment threshold. When the background fluorescence intensity drifts upward by more than 10% of the initial judgment threshold and the total number of valid droplets decreases to less than 12,000, the smoothed moving average of the background fluorescence signal in the previous 50 cycles is retrieved, the distribution range of background fluorescence noise is recalculated, and the fluorescence signal judgment threshold is shifted in the same direction according to the absolute deviation of the background mean drift. After reclassifying positive and negative droplets, the absolute copy number calculation is corrected to reduce false positive or false negative identification caused by background drift.

[0054] Example 6: In this example, genomic deoxyribonucleic acid (DNA) of astrocytes exposed to a low dose of exogenous substances for 24 hours was extracted. The DNA was treated with bisulfite reagent to deamination of unmethylated cytosine into uracil, while methylated cytosine remained unchanged. Methylation-specific primer pairs and non-methylation-specific primer pairs targeting the 12 CpG sites in the GLT-1 gene promoter region were selected. The cycle thresholds of the two types of amplification products were measured in parallel in a real-time polymerase chain reaction (RT-PCR) system. The relative amplification amounts of methylated and non-methylated specific amplification products were calculated based on these cycle thresholds. The percentage of CpG island methylation in the GLT-1 gene promoter region was obtained by using the ratio of the relative amplification amount of methylated specific amplification products to the sum of the relative amplification amounts of the two types of amplification products. .

[0055] Transcription processing index Percentage of CpG island methylation in the GLT-1 gene promoter region Multiply by each product to obtain the overall toxicity index. : In long-term toxicity screening with an exposure time of 24 hours, the comprehensive toxicity index was interval-calibrated using samples with different toxicity states. and The samples were used as the acute metabolic depression neurotoxicity marker group. and The samples were used as the epigenetic silent slow toxicity marker group. and The samples were used as the non-neurotoxic calibration group; the comprehensive toxicity index of each calibration group was calculated, and the corresponding value range was determined according to the actual distribution of the comprehensive toxicity index of each group.

[0056] After completing the above calibration, the astrocytes to be tested were obtained in the same manner. and And calculate ,in accordance with The output distinguishes the result based on the preset value range. When the value falls within the corresponding range for acute metabolic inhibition neurotoxicity, the result of the acute metabolic inhibition neurotoxicity assessment is output; when... When the result falls within the corresponding interval for epigenetic silent slow toxicity, the epigenetic silent slow toxicity determination result is output; when... When the cell falls within the non-neurotoxic range, a non-neurotoxic determination result is output, thereby completing the classification and assessment of different neurotoxic states of isolated astrocytes.

[0057] Example 7: This example evaluates the analytical sensitivity, limit of detection, and minimum detectable cell quantity performance of the GLT-1 transcriptional processing index-based detection method, and compares it with the conventional terminal injury index method; primary rat astrocytes were used according to... and Gradual inoculation was performed, with each step including a hypoxia-glucose treatment group (exposed for 2 hours and reoxygenated and reglucose for 4 hours) and a normoxic control group, each with 6 parallel replicates. After toxic exposure, total ribonucleic acid was extracted from cells at each step, with corresponding total ribonucleic acid yields of approximately 140 ng, 68 ng, 13.5 ng, 6.6 ng, 1.3 ng, 0.65 ng, and 0.13 ng, respectively.

[0058] A method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels was used. Deoxyribonuclease I was added to each step group of samples to eliminate genomic DNA interference. Specific primer pairs (preGLT1-F / R, matGLT1-F / R, and ACTB-F / R) were used to construct reaction systems for real-time quantitative polymerase chain reaction (qPCR) amplification. Degradation index (Rdeg) was confirmed to be less than 1.80 by internal control degradation monitoring. The cycle threshold was measured, and the normalized change in the cycle threshold of unspliced ​​precursor ribonucleic acid was calculated. Normalized change in the mature ribonucleic acid cycling threshold Obtain the transcription processing index Its coefficient of variation (CV); and cell viability was determined in parallel using the tetrazolium salt colorimetric method. The enzyme release rate of the supernatant was determined by the lactate dehydrogenase release method.

[0059] The test results showed that: to Cell / well tiered intervals, treatment group The concentrations stabilized between 0.2520 and 0.2645 (CV < 4.5%), all falling within the severe cytotoxicity threshold of ≤ 0.35 (P < 0.001). At this point, cell viability as measured by the tetrazolium salt colorimetric assay remained above 91%, and there was no significant difference in lactate dehydrogenase release rate, indicating a significant lag in terminal phase indicators during the early sublethal stage. When cells were diluted to 5 × 10³ cells / well (approximately 6.6 ng of total nucleic acid), the method of this invention... The value was 0.2710 with significant differences between groups (P<0.001), while the tetrazolium salt colorimetric method readings showed no statistical difference due to near-baseline noise (P>0.05). The coefficient of variation of the lactate dehydrogenase method increased to 18.4% and lost its quantitative ability; when cells were diluted to When the total nucleic acid content is approximately 1.3 ng, the treatment group The value was 0.2483 (CV 5.1%, P < 0.001), and it still output the severe toxicity judgment result with high stability, while the two terminal indicators had fallen into the blank background interval and were completely invalid; when the cells were infinitesimally diluted to 5 × 10² cells / well (total nucleic acid approximately 0.65 ng), the treatment group The coefficient of variation was 0.2835 (CV of 7.6%), indicating a statistically significant difference between the two groups (P<0.01). When further diluted to 1×10² cells / well, the coefficient of variation for amplification repeat detection exceeded 16.5%, making steady-state reproducibility impossible.

[0060] The gradient dilution comparison experiment showed that the detection method based on the GLT-1 transcriptional processing index has a minimum detectable cell quantity of 5×10² cells, with an optimal minimum detectable cell quantity of 1×10³ cells and a minimum detectable total ribonucleic acid quantity of 0.65 ng. Compared with the conventional terminal injury index method, the detection sensitivity and limit of detection of this method are improved by 10 to 20 times. While achieving accurate identification of early sublethal injury, it also broadens the detection scope under the condition of trace nerve cell samples.

[0061] The above description is only a few preferred embodiments of the present invention and an explanation of the technical principles used. Those skilled in the art should understand that the scope of the invention involved in the embodiments of the present invention is not limited to the technical solutions formed by a specific combination of the above-mentioned technical features, but should also cover other technical solutions formed by any combination of the above-mentioned technical features or their equivalent features without departing from the above-mentioned inventive concept. For example, technical solutions formed by replacing the above-mentioned features with, but not limited to, the technical features with similar functions disclosed in the embodiments of the present invention.

Claims

1. A method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels, characterized in that, Includes the following steps: Step S1: Obtain total ribonucleic acid samples of astrocytes to be tested after toxic exposure treatment and total ribonucleic acid samples of untreated control astrocytes; Step S2: Using the total ribonucleic acid (RNA) samples of astrocytes to be tested and the total RNA samples of astrocytes in the control group as templates, a reaction system containing specific primer pairs was constructed. The quantitative amplification signals of the unspliced ​​precursor RNA target of the GLT-1 gene, the mature RNA target of the GLT-1 gene, and the mature RNA target of the internal reference gene were measured in parallel in both groups of samples. Among them, the amplification region of the unspliced ​​precursor RNA target spans the intron-exon junction region of the GLT-1 gene, and the amplification region of the mature RNA target spans the exon-exon splicing junction region of the GLT-1 gene. Step S3: Based on the measured quantitative amplification signal, calculate the relative change in the expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the relative change in the expression of the mature ribonucleic acid of the GLT-1 gene in the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group. Step S4: Calculate the ratio of the relative change in expression of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the relative change in expression of the mature ribonucleic acid of the GLT-1 gene to obtain the transcriptional processing index; Step S5: Compare the transcriptional processing index with the preset toxicity threshold window and output the cellular neurotoxicity level determination result of the astrocytes to be tested.

2. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, When constructing the reaction system containing specific primer pairs in step S2, the following sub-steps are included: Step S21, adding deoxyribonuclease to the total ribonucleic acid sample of astrocytes to be tested and the total ribonucleic acid sample of astrocytes in the control group for digestion; Step S22, adding specific primer pairs targeting unspliced ​​precursor ribonucleic acid to the reaction system, wherein the 3' end sequence of the upstream primer of the specific primer pair spans the binding site between intron 1 and exon 2 of the GLT-1 gene.

3. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, In step S2, when the quantitative amplification signal is measured in parallel, a quality control step for the degradation status of ribonucleic acid is included. The quality control step for the degradation status includes the following sub-steps: Step S23, using specific primer pairs targeting the 3' and 5' ends of the internal reference gene, the quantitative amplification signal of the mature ribonucleic acid of the internal reference gene at the 3' end and the quantitative amplification signal at the 5' end are measured respectively; Step S24, the ratio of the quantitative amplification signal at the 3' end to the quantitative amplification signal at the 5' end is calculated to obtain the degradation index; Step S25, the degradation index is compared with a preset integrity threshold. When the degradation index is higher than the preset integrity threshold, the quantitative amplification signal data of the corresponding sample is discarded.

4. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, In step S2, the quantitative amplification signal is the cycle threshold measured by real-time quantitative polymerase chain reaction; in step S4, the transcriptional processing index is calculated. The calculation formula is as follows: ,in, This represents the normalized change in the GLT-1 gene unspliced ​​precursor ribonucleic acid (GLT-1) cycling threshold between the tested astrocyte total ribonucleic acid sample and the control astrocyte total ribonucleic acid sample. The normalized change in the GLT-1 gene mature ribonucleic acid cycling threshold of the total ribonucleic acid sample of the astrocytes to be tested relative to the total ribonucleic acid sample of the control group is shown.

5. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 4, characterized in that, In step S5, the preset toxicity threshold window includes a severe toxicity threshold of 0.35 and a moderate stress threshold of 0.75; when the calculated transcriptional processing index is obtained... When the value is less than or equal to 0.35, the output indicates that the tested astrocytes exhibit severe cytotoxicity and GLT-1 gene transcriptional repression; when the transcriptional processing index is less than or equal to 0.35, the output indicates that the tested astrocytes have severe cytotoxicity and GLT-1 gene transcriptional repression. When the value is greater than 0.35 and less than or equal to 0.75, the output indicates that the tested astrocytes exhibit moderate cellular neurotoxicity and metabolic stress; when the transcriptional processing index... When the value is greater than 0.75, the result of determining whether the astrocytes to be tested have no cellular neurotoxicity is output.

6. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, In step S2, quantification is performed using a multiplex microfluidic digital polymerase chain reaction. The reaction system contains a first fluorescently labeled probe targeting the unspliced ​​precursor ribonucleic acid (RRNA) of the GLT-1 gene, a second fluorescently labeled probe targeting the mature RRNA of the GLT-1 gene, and a third fluorescently labeled probe targeting the mature RRNA of the internal reference gene. The fluorescence signal of the microfluidic reaction droplets is read, and the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene and the absolute copy number of the mature RRNA of the GLT-1 gene are calculated based on the Poisson distribution model. In step S4, the direct ratio of the absolute copy number of the unspliced ​​precursor ribonucleic acid of the GLT-1 gene to the absolute copy number of the mature RRNA of the GLT-1 gene is used as the absolute transcriptional processing index.

7. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, Following step S5, the following sub-steps are included: Step S51, extracting the genomic deoxyribonucleic acid of the astrocytes to be tested after toxic exposure treatment, and after bisulfite treatment, determining the methylation percentage of the CpG island in the promoter region of the GLT-1 gene using methylation-specific polymerase chain reaction; Step S52, multiplying the transcriptional processing index by the methylation percentage to obtain a comprehensive toxicity index, and outputting the differentiation results characterizing acute metabolic repression neurotoxicity and epigenetic silent chronic toxicity based on the range of values ​​of the comprehensive toxicity index.

8. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, In step S1, the toxicity exposure treatment involves adding the test compound to a culture system containing astrocytes and incubating it.

9. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, The target site of the internal reference gene mature ribonucleic acid is the mature ribonucleic acid of the ACTB gene in rodents; the amplification region of the target site of the mature ribonucleic acid of the GLT-1 gene spans the splicing junction region of exon 4 and exon 5 of the GLT-1 gene.

10. The method for detecting cellular neurotoxicity based on GLT-1 transcriptional levels according to claim 1, characterized in that, In step S1, the toxicity exposure treatment involves placing the culture system containing astrocytes in a hypoxic and hypoglycemic environment for induction, followed by normoxic and reglycosuria reperfusion after induction.

Citation Information

Patent Citations

  • Probe for cRNA in-situ hybridization of EAAT2 (Excitatory amino acid transporter 2) gene and designing method of probe

    CN102605051B